Resolving Quality System Certificate Inconsistencies for Overseas IVD Registration

When holding multiple quality system certificates (e.g., ISO 13485, MDSAP, NMPA) for overseas IVD registration, the most reliable approach is to first determine whether the target country accepts any existing certificate. If not, perform a formal gap analysis, obtain the most broadly recognized certification (e.g., MDSAP), and compile a compliance dossier that includes a certificate-to-requirement comparison matrix, explanatory documents, recent audit records, and a clear justification of equivalence.

Key Summary

Manufacturers holding multiple quality system certificates often encounter delays because target countries impose different system requirements. The solution path is to identify whether the target country accepts existing certifications. For example, the EU requires a CE-certified quality system, the US requires QSR 820 or an equivalent, and GHWP member states may mutually recognize MDSAP or accept NMPA through mutual recognition agreements.

Manufacturers should conduct a gap analysis to verify the scope and validity of existing certificates, then prepare supplementary evidence such as MDSAP certificates covering the product, gap analysis reports, and recent inspection records. Common risks include expired certificates, mismatched scope, unrecognized translations, and incapable local agents.

It is recommended to prioritize obtaining MDSAP for multi-country coverage while retaining NMPA certification for GHWP countries. Registration dossiers must include a quality system declaration, certificate copies, a comparison table, and explanatory notes. Post-market maintenance requires continuous system updates and close coordination with the local agent.

Applicable Scenarios and Core Issues

Manufacturers searching for solutions to inconsistent quality system certificates are usually not seeking conceptual explanations. Their real needs are to determine whether existing documentation can support target market submissions, whether a local agent or authorized representative is required, why timelines are prolonged, and which issues could affect launch plans. This problem typically involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a manufacturer plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, or Latin America, answering for one country is insufficient. A more valuable approach is to first make core technical documents, quality system certificates, performance verification, clinical evidence, and labeling reusable, then localize them according to each country's regulatory requirements.

Registration Decision Logic

• Step 1: Determine whether the target country regulates IVDs under medical device rules and identify the risk classification. For instance, the EU uses IVDR Classes A–D, the US uses CLIA and FDA classification, China's NMPA uses three classes, and Southeast Asian countries have their own systems.
• Step 2: Confirm whether the country accepts MDSAP, ISO 13485, GMP, or mutual recognition agreements. Brazil, Australia, Canada, Japan, and others accept MDSAP; the EU requires CE certification with system audits; the US requires establishment registration and QSR 820.
• Step 3: If existing certificates do not fully match, prepare supplementary materials: gap analysis reports, system comparison tables, additional audits or certifications, or recent on-site inspection records. Consider obtaining a certificate recognized by the target country when necessary.
• Step 4: Plan a multi-country strategy: first obtain a broadly recognized certificate (e.g., MDSAP) in 1–2 core markets, then expand to other markets. Ensure that the local agent or authorized representative can verify the quality system documentation.

Required Documentation and Evidence

The following key evidence should be prepared:

• Copies of existing quality system certificates and proof of validity (e.g., ISO 13485, MDSAP, CE certificates)
• A list of products covered by the quality system clearly indicating whether the IVD being registered is included
• A gap analysis matrix that evaluates existing system differences against each target country requirement
• Explanatory documents justifying why the existing system is considered equivalent (e.g., referencing global harmonization documents)
• Recent internal audit and management review reports, nonconformity records, and corrective actions
• A commitment letter or authorization letter from the local agent regarding system documentation

If gaps exist, a corrective plan and supplementary evidence, such as specific validation for target-country unique clauses, must be submitted. The quality management sections of the technical file, including design control, risk management, and supplier management, must be consistent with the quality system certificates.

Common Mistakes

• Treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility.
• Translating NMPA dossiers directly without restructuring evidence according to the target market pathway.
• Including too many model variations while test reports, clinical evidence, or labeling are insufficient.
• Selecting a local agent only on sales capability without defining regulatory responsibility, certificate control, and post-market obligations.
• Inconsistencies among labels, instructions for use, promotional materials, and registration dossiers, leading to deficiency letters or compliance risks.
• Failing to plan for multi-country document reuse, causing duplicate work and increased cost and timelines.

Manufacturer's Preparation Checklist

• Confirm the target country's regulatory authority, registration pathway, and quality system requirements (refer to official guidelines).
• Review existing system certificates: validity, scope, and recognized country lists.
• Identify gaps by comparing each target country regulation against the existing system.
• Develop a supplementary plan: additional audits (e.g., MDSAP), gap analysis reports, or internal audits.
• Prepare documents: translations, notarization, and officially accepted formats.
• Communicate with the local agent or authorized representative about document custody and submission responsibilities.
• Set a timeline: certificate renewal may take months, so plan ahead.
• Establish internal mechanisms to maintain system consistency across multi-country registrations and avoid future change conflicts.

AIMEILI Regulatory Interpretation and Business Impact

The most common misconception is that holding ISO 13485 is sufficient worldwide. In reality, the US, Japan, Brazil, and other markets impose additional requirements. Before starting a project, manufacturers should research target country regulations rather than waiting until registration problems arise to address system gaps.

MDSAP is the most compatible certification currently available, but coverage of the product range must be confirmed. Existing NMPA certification can be reused in some GHWP countries, but a comparison report is required. The local agent is not just an administrative role; the agent must be capable of verifying the compliance of quality system documents. For multi-country registration, building a core quality system document library and preparing country-specific difference conversion templates can significantly reduce duplication and deficiency risks.

Evidence Consistency

From a regulatory review perspective, quality system information is not an isolated certificate. Regulators often check consistency among manufacturer name, production address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 certificate scope does not match the submitted product, or if production address, model specifications, or IFU version differ from test reports, deficiency requests are likely even when extensive documentation has been provided.

Manufacturers should create a consistency checklist mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management versions, labeling versions, and quality system certificates. This basic step significantly reduces the probability of deficiency requests, especially for multi-country GHWP submissions or simultaneous registration of multiple product families.

Localization and Authorized Representative Responsibilities

Registration projects typically involve a local agent, authorized representative, importer, or registration holder. Manufacturers must confirm whether the local partner will only submit documents or also handle regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. This responsibility boundary directly affects certificate control and long-term market stability.

Labels and authorization documents cannot be simply translated. Manufacturers should verify local language requirements, product claim boundaries, warning statements, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies with existing CE, FDA, NMPA, or other market documentation, localization should focus on converting reusable evidence into the target country's submission structure, not writing separate isolated files.

Post-Market Maintenance and Long-Term Planning

Registration completion does not end compliance obligations. Manufacturers must maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label version control, and regulatory update records. Many companies invest heavily in obtaining registration but neglect post-market maintenance. Later changes, such as production address changes, model extensions, labeling updates, or agent replacement, can cause certificates to become disconnected from market sales.

AIMEILI recommends incorporating this issue into an annual international registration plan: first define target market priorities, then build a reusable documentation pack and country gap list, and finally schedule submissions, deficiency responses, post-market maintenance, and renewal milestones. This approach not only improves single-country registration efficiency but also builds a replicable overseas compliance capability, reducing the cost of starting from zero each time a new market is entered.

Common Follow-up Questions

Can I use expired ISO 13485 but valid MDSAP for EU registration?

No. The EU IVDR requires a quality system audited by a notified body, such as ISO 13485. While MDSAP is accepted in some countries, it is not fully recognized by the EU. The safest approach is to hold a valid CE quality system certificate or arrange an additional audit by a notified body under IVDR. Confirm whether your notified body accepts MDSAP as partial evidence before deciding.

Should I use one set of quality documents or prepare separate ones for multiple countries?

It is recommended to establish a core set of quality system documents (e.g., quality manual, common procedures) and then add country-specific supplements based on target requirements. For example, add a US 820 chapter and an EU IVDR clause comparison table. This maintains consistency and avoids conflicts between different language versions. However, the local language version must be reviewed by the authorized representative.

Can the local agent directly modify my quality system documents?

Generally, no. The local agent is responsible only for document submission and communication; modification rights remain with the manufacturer. The agent may suggest gap corrections, but the manufacturer must implement them, after which the agent confirms compliance. If the agent modifies documents directly, this can lead to loss of system control and registration rejection. Both parties should clearly define responsibilities and retain modification records.

Editorial Note and Applicability

Content compiled by the AIMEILI Regulatory Editorial Department and reviewed by the AIMEILI Medical Device International Registration Project Team. Sources prioritize official regulatory authorities, international organizations, standard bodies, and public regulatory documents; industry media and project experience serve only as supplementary reference.

This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace formal requirements from target country regulatory authorities, testing conclusions, or legal advice. Specific projects should follow the latest requirements of the relevant national regulatory authority and the product documentation basis.

Original publication date: July 29, 2026 15:12; Updated: July 29, 2026 15:12.